MRD + Cells Assay
Flow cytometry is a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response in bone marrow of multiple myeloma after therapy. An optimized antibodies panel validated by Euroflow detect minimal numbers of plasmatic cells in multiple myeloma (10-2 – 10-4). For the measurement of these specific population of cells with the presence and absence of a drug and in different concentration we can valuate drug efficacy in these very resistant subset of cells.
Tubeandbracket
  • MM
Native Blook Cell Populations
  • Red Blood Cells
  • Platelets
  • Plasmatic Cells
  • Others

Directed Toxicity against

Tarjet Arrow
Cytotoxic Drug Therapy
Plate

Hematological
Sample

Native Cell
Population

Drug
Incubation

Cells Retrieval &
FCM Readout

MRD + Cells Assay:
Native Environment

Hematological
Sample
Tubeandbracket
  • MM
Native Cell Population
Native Blook Cell Populations
  • Red Blood Cells
  • Platelets
  • Plasmatic Cells
  • Others
Drug Incubation
Directed Toxicity against
Residual Plasma Cells
Tarjet Arrow
Cytotoxic Drug Therapy
Cells Retrieval & FCM Readout
Plate
MRD + Cells Assay:
Native Environment
Hematoxicity Assay